Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Study of the Efficacy and Safety of 9MW0813 and Aflibercept (EYLEA®) in Patients With Diabetic Macular Edema (DME) in a Multicenter, Randomized, Double-blind, Parallel Active-controlled Study

NCT05324774 is registered in ClinicalTrials.gov with Mabwell (Shanghai) Bioscience Co., Ltd. as lead sponsor.

NCT NCT05324774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05324774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Study of the Efficacy and Safety of 9MW0813 and Aflibercept (EYLEA®) in Patients With Diabetic Macular Edema (DME) in a Multicenter, Randomized, Double-blind, Parallel Active-controlled Study
Lead sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
February 28, 2022
Completion date
July 30, 2024
Enrollment
346 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema